Clopidogrel News and Research

RSS

Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Edoxaban-based dual therapy noninferior to standard treatment in atrial fibrillation post-stenting

Edoxaban in combination with a P2Y12 inhibitor is noninferior to standard triple therapy for preventing bleeding in patients with atrial fibrillation after coronary stenting.

4 Sep 2019

People with stroke can take common medicines without raising risk of another stroke

People who suffer a stroke caused by bleeding in the brain - known as brain hemorrhage - can take common medicines without raising their risk of another stroke, a major clinical trial has found.

23 May 2019

Scientists solve mystery surrounding mechanical forces that influence blood clotting

Researchers at the University of Sydney have used biomechanical engineering techniques to unlock the mystery surrounding the mechanical forces that influence blood clotting.

5 Apr 2019

Study shows ticagrelor is equally safe and effective as clopidogrel after heart attack

Patients given clot busters to treat a heart attack fared equally well if they were given the standard blood thinning medication clopidogrel versus the newer, more potent drug ticagrelor, according to research presented at the American College of Cardiology's 68thAnnual Scientific Session.

19 Mar 2019

Study indicates the benefits of stopping aspirin in heart attack patients

Patients who stopped taking aspirin three months after receiving a stent to open the heart's arteries but continued taking a P2Y12inhibitor—clopidogrel, prasugrel or ticagrelor—did not experience higher rates of death from any cause, heart attack or stroke after a year compared with those receiving standard therapy, according to research presented at the American College of Cardiology's 68thAnnual Scientific Session.

19 Mar 2019

Access to real-time genotype data influences prescriber behavior after PCI

Today, in a late-breaking featured clinical research session at the American College of Cardiology Scientific Sessions 2018, researchers from Penn Medicine present first-of-its-kind data on the impact of real-time CYP2C19 genotype results when prescribing antiplatelet drugs in the clinic.

13 Mar 2019

Combination treatment lowers risk of ischemic stroke recurrence

Stroke survivors taking a combination of the blood thinner cilostazol with aspirin or clopidogrel had a lower risk of ischemic stroke recurrence than those who received aspirin or clopidogrel alone, according to late breaking science presented at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.

7 Feb 2019

Patients taking anti-depressants more likely to develop gastrointestinal bleeding

Patients taking anti-depressant medications classified as selective serotonin reuptake inhibitors are 40 percent more likely to develop severe gastrointestinal bleeding, particularly when they also use common over-the-counter pain relievers, according to a research review in the Journal of the American Osteopathic Association.

31 Jan 2019

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

Experimental vaccine shows promise to protect stroke survivors from blood clots

A vaccine may one day be able to replace oral blood thinners to reduce the risk of secondary strokes caused by blood clots, without increasing the risk of serious bleeding or triggering an autoimmune response, according to new research in the American Heart Association's journal Hypertension.

29 Oct 2018

Study aims to understand role of clopidogrel in patients with cardiovascular disease

Platelet inhibition with aspirin is the cornerstone of medical therapy for coronary artery disease. In the era of percutaneous coronary intervention with drug-eluting stents, dual anti-platelet therapy with the addition of clopidogrel became the mainstay of therapy.

11 Sep 2018

Antiplatelet monotherapy appears to be safer but does not reduce risk of heart attack

Long-term antiplatelet monotherapy after stenting is safe but does not reduce the risk of death or heart attack compared to standard dual antiplatelet therapy, according to late breaking results from the GLOBAL LEADERS trial presented today in a Hot Line Session at ESC Congress 2018 and published in The Lancet.

27 Aug 2018

Mono-antiplatelet therapy after aortic heart valve replacements may work as well as two drugs

Current treatment guidelines say patients who undergo minimally invasive aortic heart valve replacements should receive two antiplatelet drugs to reduce the risk of dangerous blood clots.

14 Aug 2018

Clot busting drug combo reduces risk of major strokes in high risk patients

In patients who have had a minor stroke or a transient ischemic stroke (TIA), the risk of getting a full-blown stroke or a major stroke is high. A new study has found that these high-risk individuals, when prescribed with clot-preventing drugs clopidogrel along with aspirin show a lower risk of getting major stroke.

18 May 2018

Drug combination may prevent secondary stroke in certain patients, study shows

Results from an international clinical trial of more than 4880 participants, published in the New England Journal of Medicine, show that combining clopidogrel and aspirin following a small stroke or experiencing minor stroke symptoms decreases risk of a new stroke, heart attack or other ischemic event within 90 days.

17 May 2018

Taking clot-preventing drug with aspirin may lower risk of major stroke, finds study

The research was part of the Platelet-Oriented Inhibition in New TIA and minor ischemic stroke trial -- a randomized, double-blind, placebo-controlled trial conducted between May 2010 and December 2017.

16 May 2018

Genetic testing could help guide blood-thinner treatment after stent placement

Using genetic testing to inform which blood thinner to use following a procedure to open narrowed blood vessels resulted in significantly fewer complications among patients, according to new research in Circulation: Genomic and Precision Medicine, an American Heart Association journal.

3 Apr 2018

Patients given six-month dual antiplatelet therapy have increased heart attack risk

The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in patients with acute coronary syndrome who were randomly assigned to receive dual antiplatelet therapy for either six months or at least 12 months after receiving a drug-eluting stent.

13 Mar 2018

Two anticlotting medicines better at reducing bleeding risk than triple therapy

Using just two anticlotting medicines for patients who have atrial fibrillation and have had a stent placed in a heart artery is safer than using the current standard treatment of three medications, according to a new study presented by Brigham and Women's Hospital cardiologist Christopher Cannon, MD, at the European Society of Cardiology and published simultaneously in The New England Journal of Medicine.

28 Aug 2017

New ESC Focused Update provides recommendations on DAPT in patients with coronary artery disease

The first ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease is published online today in European Heart Journal, and on the ESC website.

26 Aug 2017